KATP channel pharmacogenomics: From bench to bedside

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 354-357

  Sattiraju, S ^a   Reyes, S ^a   Kane, G C ^a   Terzic, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIAZOXIDE; INSULIN; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CELL ENERGY; CLINICAL DECISION MAKING; DIABETES MELLITUS; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; HOMEOSTASIS; HUMAN; HYPERINSULINEMIC HYPOGLYCEMIA; HYPOGLYCEMIA; INHERITANCE; INSULIN RELEASE; MEMBRANE DEPOLARIZATION; MOLECULAR DYNAMICS; NEWBORN DISEASE; PHARMACOGENOMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATP-BINDING CASSETTE TRANSPORTERS; DIABETES MELLITUS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INSULIN; INSULIN-SECRETING CELLS; KATP CHANNELS; PATIENT SELECTION; PERSISTENT HYPERINSULINEMIA HYPOGLYCEMIA OF INFANCY; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG;

EID: 38349093358     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100378     Document Type: Article

References (35)

1. Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
2. Giacomini, K.M. et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81, 328-345 (2007).
3. Weinshilboum, R.M. & Wang, L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006).
4. Kane, G.C., Liu, X.-K., Yamada, S., Olson, T.M. & Terzic, A. Cardiac KATP channels in health and disease. J. Mol. Cell. Cardiol. 38, 937-943 (2005).
5. Jahangir, A. & Terzic, A. KATP channel therapeutics at the bedside. J. Mol. Cell. Cardiol. 39, 99-112 (2005).
6. Pearson, E.R. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355, 467-477 (2006).
7. Babenko, A.P. et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456-466 (2006).
8. Gloyn, A.L. et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
9. Gloyn, A.L. et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum. Mol. Genet. 14, 925-934 (2005).
10. Landau, Z. et al. Sulfonylurea-responsive diabetes in childhood. J. Pediatr. 150, 553-555 (2007).
11. Flanagan, S.E. et al. Mutations in KATP channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56, 1930-1937 (2007).
12. Proks, P., Girard, C., Baevre, H., Njolstad, P.R. & Ashcroft, F.M. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy. Diabetes 55, 1731-1737 (2006).
13. Proks, P. et al. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep. 6, 470-475 (2005).
14. Proks, P. et al. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc. Natl. Acad. Sci. USA 101, 17539-17544 (2004).
15. + channel channel/enzyme multimer: metabolic gating in the heart. J. Mol. Cell. Cardiol. 38, 895-905 (2005).
16. Proks, P. et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum. Mol. Genet. 15, 1793-1800 (2006).
17. Masia, R. et al. A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes 56, 1357-1362 (2007).
18. Zung, A., Glaser, B., Nimri, R. & Zadik, Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab. 89, 5504-5507 (2004).
19. Sagen, J.V. et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53, 2713-2718 (2004).
20. ATP channels. Pediatric Diabetes 6, 103-113 (2005).
21. Dekelbab, B.H. & Sperling, M.A. Recent advances in hyperinsulinemic hypoglycemia of infancy. Acta Paediatr. 95, 1157-1164 (2006).
22. Thomas, P.M. et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426-429 (1995).
23. Nestorowicz, A. et al. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes 46, 1743-1748 (1997).
24. Huopio, H. et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J. Clin. Invest. 106, 897-906 (2000).
25. Magge, S.N. et al. Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of the b-cell sulfonylurea receptor. J. Clin. Endocrinol. Metab. 89, 4450-4456 (2004).
26. Dunne, M.J., Cosgrove, K.E., Shepherd, R.M., Aynsley-Green, A. & Lindley, K.J. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol. Rev. 84, 239-275 (2004).
27. Glaser, B., Thornton, P., Otonkoski, T. & Junien, C. Genetics of neonatal hyperinsulinism. Arch. Dis. Child Fetal Neonatal Ed. 82, F79-F86 (2000).
28. Ashcroft, F.M. ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 115, 2047-2058 (2005).
29. Thomas, P., Ye, Y. & Lightner, E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet. 5, 1809-1812 (1996).
30. ATP channel causes maladaptive remodeling and heart failure in hypertension. Hum. Mol. Genet. 15, 2285-2297 (2006).
31. + channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J. Physiol. 577, 1053-1065 (2006).
32. ATP channel gating. Nat. Genet. 36, 382-387 (2004).
33. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med. 4, 110-116 (2007).
34. ATP channels by ATP and protons in two Kir6.2 polymorphisms found in sudden cardiac death. Physiol. Genomics 25, 105-115 (2006).
35. Waldman, S.A., Christensen, N.B., Moore, J.E. & Terzic, A. Clinical pharmacology: the science of therapeutics. Clin. Pharmacol. Ther. 81, 3-6 (2007).